|
Abnormality of metabolism/homeostasis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Acidosis, Lactic
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The currently available α-glucosidase inhibitors, for instance, acarbose have some side effects such as hypoglycemia at higher doses, liver problems, meteorism, diarrhea, and lactic acidosis.
|
31553294 |
2020 |
|
Acrokeratoelastoidosis of Costa
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Finally, we showed that AKE significantly inhibits α-glucosidase activity in vitro.
|
28622482 |
2017 |
|
Adenocarcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Thus, the specificity and ubiquity of sucrase-isomaltase expression in adenocarcinomas of the colon can be exploited to improve the clinical management of this disease.
|
1707385 |
1991 |
|
Adenocarcinoma
|
0.040 |
Biomarker
|
group |
BEFREE |
Immunohistochemical localization showed that SI was directed to the apical membrane in Barrett's epithelium in contrast to a more diffuse cytoplasmic pattern in esophageal adenocarcinomas.
|
8359653 |
1993 |
|
Adenocarcinoma
|
0.040 |
Biomarker
|
group |
BEFREE |
Of 14 cardia adenocarcinomas that were SI negative, 100% (14/14) had no associated Barrett's mucosa.
|
8893584 |
1996 |
|
Adenocarcinoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
This phenolic-rich extract inhibited the lipid oxidation of Wistar rat brain (IC<sub>50</sub> = 863.0 mg GAE/L), inhibited α-glucosidase activity (IC<sub>50</sub> = 435.4 µg/mL), protected human erythrocytes against mechanical hemolysis at different osmolarity conditions, and showed cytotoxic/antiproliferative effects against human ileocecal adenocarcinoma cells (HCT8; IC<sub>50</sub> = 552.6 µg/mL) but no cytotoxicity toward noncancerous human lung fibroblast (IMR90).
|
31721214 |
2019 |
|
Adenocarcinoma of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study shows that the expression of enzymatically active sucrase-isomaltase is a ubiquitous property of primary and metastatic colon adenocarcinoma.
|
1707385 |
1991 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this work, phenol-rich extracts from 'Cornicabra' and 'Picual' virgin-olive oils (EVOOs) were examined, for the first time, to establish their capacity to inhibit key enzymes involved in Alzheimer's disease (AD) (acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and 5-lipoxygenase (LOX)), major depressive disorder (MDD) and Parkinson's disease (PD) (monoamine oxidases: hMAO-A and hMAO-B respectively), and diabetes mellitus (DM) (α-glucosidase and α-amylase).
|
29579961 |
2018 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study sets out to investigate into antioxidant and inhibitory activities of O. argyrea extracts (ethyl acetate, methanol, and water) against key enzymes linked to diabetes (α-amylase, α-glucosidase), Alzheimer's disease (acetylcholinesterase, butyrylcholinesterase), and skin hyperpigmentation (tyrosinase).
|
30081342 |
2018 |
|
Alzheimer's Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
EAE was the most effective enzyme inhibitor, exhibiting the highest inhibition against some enzymes linked to Alzheimer's disease (cholinesterases), diabetes mellitus (α-glucosidase and α-amylase) and hyperpigmentation problems (tyrosinase).
|
30466026 |
2019 |
|
Alzheimer's Disease
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to evaluate the inhibitory effects against Alzheimer's disease-related enzymes Acetylcholinesterase (AChE) and Butyrylcholinesterase (BuChE), diabetes mellitus related enzymes α-glucosidase and α-amylase.
|
30213283 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Disease-related changes in glycogen, glucose, and α-glucosidase activity are also found in spinal cord tissue samples of autopsied patients with ALS.
|
23754387 |
2013 |
|
atrial fibrillation new onset
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sulfonylureas, glinides, α-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were not associated with developing the risk of NAF.
|
30161122 |
2018 |
|
Barrett Epithelium
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical localization showed that SI was directed to the apical membrane in Barrett's epithelium in contrast to a more diffuse cytoplasmic pattern in esophageal adenocarcinomas.
|
8359653 |
1993 |
|
Barrett Esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Reverse transcription polymerase chain reaction was used to determine the presence of SI mRNA in Barrett's esophagus and esophageal adenocarcinomas.
|
8359653 |
1993 |
|
Barrett Esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
This suggests that SI-positive tumors may represent BA without the standard definition of Barrett's esophagus being met.
|
8893584 |
1996 |
|
Barrett's Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Detection of Barrett's adenocarcinoma of the gastric cardia with sucrase isomaltase and p53.
|
8893584 |
1996 |
|
Becker Muscular Dystrophy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We describe a case of Becker muscular dystrophy (BMD) with a remarkable reduction in activity of the acid α-glucosidase (GAA) enzyme, caused by a combination of pathogenic mutation and polymorphism variants resulting in pseudodeficiency in GAA.
|
29778277 |
2018 |
|
Blood spots
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
The screening of GSD2 through the measurement of acid alpha-glucosidase activity in dried blood spots was applied to a selected sample of 5 Mexican patients with proximal myopathies of unknown etiology.
|
20350966 |
2010 |
|
Blood spots
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
We quantified levels of acid alpha-glucosidase (GAA) from dried blood spots analyzed fluorometrically.
|
25998610 |
2015 |
|
Blood spots
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
To investigate the feasibility of newborn screening for glycogen storage disease type II (GSDII; Pompe disease or acid maltase deficiency) in the Japanese population, we assayed the acid alpha-glucosidase activity in dried blood spots from 715 Japanese newborns and 18 previously diagnosed patients using a fluorometric procedure.
|
19362502 |
2009 |
|
Blood spots
|
0.080 |
Biomarker
|
disease |
BEFREE |
Improved assay for differential diagnosis between Pompe disease and acid α-glucosidase pseudodeficiency on dried blood spots.
|
21320792 |
2011 |
|
Blood spots
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Newborn screening (NBS) for Pompe disease is done through analysis of acid α-glucosidase (GAA) activity in dried blood spots.
|
29162674 |
2017 |
|
Blood spots
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Acid α-glucosidase (GAA) activity in dried blood spots was measured and clinical data collected in 108 patients.
|
25047669 |
2014 |